By Fineline Cube Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760), the globally leading medical device innovator, announced it has re-submitted its prospectus to the Hong Kong Stock Exchange for a secondary listing. The company’s initial filing, submitted on November 10, 2025, expired on May 10, 2026, prompting the renewed application to access international capital markets.
Transaction Details
| Item | Detail |
|---|---|
| Company | Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) |
| Listing Target | Hong Kong Stock Exchange (secondary listing) |
| Initial Filing Date | November 10, 2025 |
| Expiration Date | May 10, 2026 |
| Re-filing Date | Week of May 12, 2026 |
| Primary Listing | Shenzhen Stock Exchange (SHE: 300760) |
Company Profile & Business Segments
- Core Identity: Globally leading, innovation-driven medical device company and pioneer in medical digitalization
- Strategic Portfolio: Comprehensive matrix spanning multiple product lines and clinical applications
- Key Business Segments:
- In vitro diagnostics (IVD)
- Life information and support systems
- Medical imaging solutions
- Minimally invasive surgery platforms
- Minimally invasive intervention technologies
- Clinical Coverage: Emergency departments, operating rooms, intensive care units, general wards, cardiology, clinical laboratory, and ultrasound departments
- Global Presence: Operations spanning developed and emerging markets worldwide
Financial Performance
| Metric | 2025 Results |
|---|---|
| Annual Revenue | RMB 332.82 billion (USD 50 billion) |
| Annual Profit | RMB 8.45 billion (USD 12.4 billion) |
| Revenue Growth | Consistent double-digit growth trajectory |
| Profit Margin | ~2.5% net margin (industry-typical for medical device sector) |
| Market Position | Leading Chinese medical device company with global competitiveness |
Strategic Significance
| Aspect | Details |
|---|---|
| Capital Markets Strategy | Hong Kong listing provides access to international investors and enhanced liquidity |
| Global Expansion | Secondary listing supports international growth ambitions and brand recognition |
| Industry Leadership | Demonstrates maturity and scale of China’s medical device innovation ecosystem |
| Investment Appeal | Attractive combination of growth, profitability, and market leadership in defensive healthcare sector |
The re-filing reflects Mindray’s commitment to maintaining its position at the forefront of global medical technology while providing international investors access to one of China’s most successful healthcare innovators.
Market Impact & Outlook
- Medical Device Sector | Defensive characteristics and consistent demand make attractive investment during economic uncertainty
- China Healthcare Story | Represents premium exposure to China’s healthcare modernization and domestic innovation themes
- Valuation Implications | Hong Kong listing may command premium valuation compared to mainland trading
- Competitive Positioning | Strong positioning against global medtech leaders including GE Healthcare, Philips, and Siemens Healthineers
- Growth Catalysts | Continued international expansion, new product launches, and healthcare infrastructure development in emerging markets
Forward‑Looking Statements
This brief contains forward-looking statements regarding listing applications, financial performance, market opportunities, and strategic objectives. Actual results may differ due to risks including regulatory approvals, market conditions, competitive dynamics, and global economic factors.-Fineline Info & Tech